MBRX — Moleculin Biotech, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1659617 ·
Last close
$6.83
Market Cap
$6.96M
52W High
$106.00
52W Low
$3.13
ADV30
35,485
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -7,561,000 | -7,635,000 | 21,087,000 | 7,262,000 | 9,500,000 |
| Mar 2026 | 0 | — | -7,874,000 | -12,845,000 | 23,363,000 | 10,317,000 | 8,180,000 |
| Dec 2025 | 0 | — | -7,533,000 | 15,552,000 | 22,126,000 | 8,878,000 | 7,120,000 |
| Sep 2025 | 0 | — | -5,906,000 | -25,399,000 | 20,353,000 | 6,703,000 | 47,273,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,357,000
Investing CF
$0
Financing CF
$25,087,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-50.62
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-226,484,000
Inventory
—
Receivables
$4,000
ST Investments
—
EBIT TTM
$-28,874,000
Pretax Income TTM
$-30,327,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -25,103,000 | -33,560,000 | 22,126,000 | 7,120,000 | 15,006,000 | -22,735,000 |
| Dec 2024 | 0 | -26,641,000 | -26,048,000 | 16,925,000 | 5,717,000 | 11,208,000 | -23,862,000 |
| Dec 2023 | 0 | -29,631,000 | -29,769,000 | 38,217,000 | 12,144,000 | 26,073,000 | -23,591,000 |
| Dec 2022 | 0 | -30,640,000 | -29,025,000 | 57,422,000 | 5,231,000 | 52,191,000 | -27,639,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-39,964,000
OpCashFlow TTM
—
Assets (Latest)
$21,087,000
Forward EPS
$-110.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMRN | Immuron Ltd | $7.03M | $0.87 | — |
| XCUR | EXICURE, INC. | $7.07M | $1.08 | — |
| LGVN | Longeveron Inc. | $6.83M | $2.11 | — |
| CVKD | Cadrenal Therapeutics, Inc. | $6.71M | $1.88 | — |
| CURX | Curanex Pharmaceuticals Inc | $7.37M | $4.70 | — |
News headlines (Yahoo Finance, 1h cache)
Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
2026-11-18 13:35 · Yahoo
Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
2026-11-16 12:30 · Yahoo
Moleculin Secures Australian Patent for Annamycin Formulation Technology
2026-11-12 13:37 · Yahoo
Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
2026-11-10 19:45 · Yahoo
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
2026-11-04 16:00 · Yahoo
Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
2026-10-30 12:40 · Yahoo
Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial
2026-10-20 12:12 · Yahoo
Moleculin Announces Reverse Stock Split
2026-10-16 13:20 · Yahoo
Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout
2026-09-29 12:45 · Yahoo
Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR
2026-09-25 17:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.